The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal

Abstract Background Erenumab, a fully human monoclonal antibody directed against the calcitonin gene-related peptide receptor, was approved for the prevention of episodic (EM) or chronic migraine (CM) at the monthly dose of 70 mg or 140 mg. We reviewed the available literature to understand if patie...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Raffaele Ornello, Cindy Tiseo, Ilaria Frattale, Giulia Perrotta, Carmine Marini, Francesca Pistoia, Simona Sacco
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2019-10-01
Colecção:	The Journal of Headache and Pain
Assuntos:	Migraine Calcitonin gene-related peptide Migraine prevention Monoclonal antibodies Erenumab
Acesso em linha:	http://link.springer.com/article/10.1186/s10194-019-1054-4
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!